Research Overview

Immunotherapy Integrated Research Center (IIRC)

From Cell Therapies to Vaccines

T cell processing

Lab technicians process patient cells at Fred Hutch in Seattle, Washington

Photo by Robert Hood / Fred Hutch

Fred Hutch is at the forefront of a fundamental shift in the way cancer is treated and cured. Our researchers are developing new ways to empower a patient’s own immune system to do what it does naturally — fight disease — potentially with fewer side effects than conventional cancer treatments.

Our Nobel Prize-winning work on bone marrow transplantation provided the first definitive and reproducible example of the human immune system's power to cure cancer. Today, we continue to lead this revolutionary field, called immunotherapy.  

We've already used immunotherapy to boost survival rates for patients with leukemia and other blood cancers. And we've shown it has promise for treating many other cancers. These targeted therapies have the potential to one day replace blood stem cell transplantation as a cure for many blood cancers and become the first cures for some of the most challenging solid tumors, including lung, pancreatic and ovarian cancers.

Over the past decade, we have expanded our immunotherapy approaches through laboratory research and clinical trials to treat even more types of cancer. Through our Immunotherapy Integrated Research Center (IIRC) we will continue to accelerate the pace of discovery.

Labs / Research Programs

Our Faculty

Learn more about our faculty and their research into fundamental immune mechanisms and new immunotherapies.

Core research areas

The IIRC’s collaborative approach is evident in the scope of our faculty’s ongoing research. At the core is our commitment to translating a better understanding of the immune system into lifesaving new ways to control, cure and potentially prevent cancer and other serious diseases.

A number of research projects are underway, from laboratory research and clinical trials to the development of better methods and tools for data analysis.

Our cancer immunotherapy research has four focus areas: adoptive T-cell therapies, antibody-based therapies, cancer vaccines and checkpoint inhibitors.

Adoptive T-cell therapy

  • Fred Hutch researchers were the first to use a melanoma patient’s own cloned T cells as the sole treatment to put his cancer into long-term remission. More than 10 years after a 52-year-old Oregon man received an infusion of 5 billion copies of his own CD4+ T cells that targeted his tumor, he continued to be cancer-free.
Dr. Stanley Riddell

Dr. Stanley Riddell

Photo by Bo Jungmayer / Fred Hutch

  • Drs. Stanley Riddell, David Maloney and Cameron Turtle have contributed important discoveries about precisely how to use T cells for cancer therapies. They are testing a kind of T-cell therapy using CAR (chimeric antigen receptor) T cells, referring to a molecule engineered to enable these T cells to target the patient's disease. Preliminary results from an ongoing clinical trial using an advanced form of CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and chronic lymphocytic leukemia has shown promising, even dramatic responses. By selecting the best T cells from each patient and carefully controlling the composition of treatments, our scientists are continuing to achieve more predictable, consistent and lasting therapeutic effects in patients. 
  • Dr. Riddell’s team has launched a clinical trial to test another CAR T-cell therapy targeting certain blood cancers as well as triple negative breast cancer and non-small cell lung cancer. And they are developing another CAR T-cell therapy for patients with multiple myeloma.
  • Drs. Oliver Press and Brian Till are developing a similar CAR T-cell therapy that will be tested for patients with certain lymphomas.
Dr. Phil Greenberg

Dr. Phil Greenberg

Photo by Robert Hood / Fred Hutch

  • Drs. Phil Greenberg, Aude Chapuis, Dan Egan and their colleagues are currently conducting clinical trials to test the safety of administering specially engineered T cells to protect more blood stem cell transplant patients with acute myeloid leukemia from a potentially life-threatening relapse. These therapeutic T cells target cells that carry a protein called WT1 that is partially responsible for cells becoming leukemic. The results to date have been encouraging. They are also planning to expand the trial to include AML patients not eligible for transplant.

  • This team, together with Dr. Sylvia Lee, is also conducting a trial of this approach for patients with advanced mesotherlioma and non-small cell lung cancer, and they are planning to launch similar T-cell therapy trials for certain patients with pancreatic cancer and ovarian cancer.
  • Dr. Seth Pollack is aiming a T-cell therapy squarely at a target called NY-ESO-1, which is found on soft tissue sarcomas as well as other tumors including some melanomas, leukemias, and lung and prostate cancers.
Dr. Sylvia Lee

Dr. Sylvia Lee

Photo by Robert Hood / Fred Hutch

  • Dr. Sylvia Lee and colleagues are looking at a type of T cell known as tumor infiltrating lymphocytes (TILs) as an option for treating melanoma and other cancers. Fred Hutch is one of only a handful of centers in the U.S. to offer patients with advanced melanoma this experimental TIL therapy, which leverages T cells that have already responded to a patient’s cancer but, for various reasons, haven’t overcome it. The treatment has led to striking responses in many patients with late-stage melanoma. Lee and her colleagues are now working to enhance this technique and extend it to patients with lung, bladder, and head and neck cancers.
  • Drs. Harlan Robins and Jason Bielas and their colleagues are also developing methods to precisely measure and characterize TILs to provide more accurate prognoses and help predict which patients are likely to respond to certain immunotherapies. The technology could also shed light on which T cells are most effective against tumors and how to design even more targeted immunotherapies in the future.
Dr. Matthias Stephan

Dr. Matthias Stephan

Photo by Scott Streble for Fred Hutch

  • Dr. Matthias Stephan, who works at the forefront of the nascent field of immunobioengineering, is developing a method to apply immunotherapy to solid malignancies like breast cancer by taking advantage of cutting-edge biomaterials. He has designed a tiny dissolving implant that concentrates immune cells directly at tumor sites where they can unite to clear away the adjacent tumor.

Antibody-based therapies

Dr. Oliver Press

Dr. Oliver Press

Photo from Fred Hutch file

  • Antibody-based therapy uses small proteins to directly attack tumors or to allow therapeutic agents to be delivered directly to cancer cells, sparing healthy cells and thus minimizing side effects. Our researchers, including Dr. David Maloney, helped to pioneer the use of an antibody for the treatment of non-Hodgkin's lymphoma, which led to the development of the first medication of its kind approved in the U.S. for the treatment of malignant disease — one of the world's top-selling cancer drugs, rituximab.

  • Dr. Oliver Press leads the field in combining the precision of antibodies with the power of radiation, crafting new radioimmunotherapies that target radiation directly to cancer cells while avoiding healthy cells. Thanks to the work of his team and other Hutch researchers, we are able to offer clinical trials of antibody therapies not available anywhere else. Combined with blood stem-cell transplantation, radioimmunotherapy has produced some of the best lymphoma cure rates in the world and reduced harmful side effects for patients over 60.  Dr. Press has also had unprecedented success in treating follicular lymphoma with radiolabeled antibodies either alone or sequentially with chemotherapy, boosting the five-year survival rate for these patients from 64 percent to 87 percent.
  • Dr. Damian Green hopes to ultimately offer a cure for multiple myeloma using a similar radioimmunotherapy approach to hunt down each cancer cell in a patient's body. The technique also has potential for other cancers of the blood and bone marrow.
  • Drs. Press and Green and their colleagues are also leading the development of a multistep delivery method for radioimmunotherapy, known as pretargeting, that allows five times more radiation therapy to reach the cancer than with standard radiation, all while avoiding healthy tissue.

Cancer vaccines

  • Our researchers have developed vaccines with the potential to not only destroy cancerous cells, but to prevent cancer relapse, just as vaccination can prevent infections such as measles and polio. Dr. Nora Disis and Fred Hutch scientists and their colleagues are testing vaccines to treat and prevent the recurrence of late-stage breast and ovarian cancers. They are also developing vaccines that could be given to high-risk women to prevent breast cancer entirely.

Checkpoint inhibitors

  • Dr. Thomas Spies and colleagues discovered a molecule, called MICA, that is released by cancer cells and acts as a shield, preventing immune cells from coming into contact with and killing the cancer cells. The researchers plan to test the therapeutic potential of an antibody they developed to neutralize MICA's immune-blocking ability.